MENU
+Compare
ABOS
Stock ticker: NASDAQ
AS OF
Nov 28 closing price
Price
$1.88
Change
-$0.07 (-3.59%)
Capitalization
118.72M

ABOS Acumen Pharmaceuticals Forecast, Technical & Fundamental Analysis

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease... Show more

ABOS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ABOS with price predictions
Nov 28, 2025

ABOS in upward trend: price rose above 50-day moving average on November 25, 2025

ABOS moved above its 50-day moving average on November 25, 2025 date and that indicates a change from a downward trend to an upward trend. In of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABOS's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 26, 2025. You may want to consider a long position or call options on ABOS as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ABOS just turned positive on November 26, 2025. Looking at past instances where ABOS's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ABOS advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

ABOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for ABOS crossed bearishly below the 50-day moving average on November 19, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ABOS entered a downward trend on November 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.268) is normal, around the industry mean (27.168). P/E Ratio (0.000) is within average values for comparable stocks, (52.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.897). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (334.447).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
ABOS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABOS is expected to report earnings to rise 4.48% to -45 cents per share on March 30

Acumen Pharmaceuticals ABOS Stock Earnings Reports
Q4'25
Est.
$-0.46
Q3'25
Beat
by $0.16
Q2'25
Missed
by $0.17
Q1'25
Beat
by $0.03
Q4'24
Missed
by $0.13
The last earnings report on November 12 showed earnings per share of -43 cents, beating the estimate of -60 cents. With 53.32K shares outstanding, the current market capitalization sits at 118.72M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
427 Park Street
Phone
+1 434 297-1000
Employees
52
Web
https://www.acumenpharm.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACHFF0.740.02
+2.16%
Arch Biopartners Inc.
TNABF3.350.01
+0.30%
Tenaga Nasional Berhad
ERELY5.57N/A
N/A
Eregli Demir Ve Celik Fabrikal
MTLRF1.70N/A
N/A
Metalore Resources Limited
PGINF4.16N/A
N/A
Prestige International Inc.

ABOS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with BEAM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-3.59%
BEAM - ABOS
44%
Loosely correlated
+1.20%
CELC - ABOS
44%
Loosely correlated
+0.79%
SYRE - ABOS
42%
Loosely correlated
+0.84%
CRBU - ABOS
40%
Loosely correlated
+3.19%
CRSP - ABOS
40%
Loosely correlated
+0.32%
More